Digital health technologies increasingly produce continuous or frequently repeated observations that could inform medication initiation, titration, monitoring, adherence support, and treatment review. Yet longitudinal availability does not guarantee longitudinal interpretability. A change in a wearable, mobile, or remotely acquired signal may reflect biological evolution, treatment response, altered behavior, sensor or platform change, data-quality deterioration, incomplete observation, or the downstream consequences of an earlier clinical intervention. Artificial intelligence can amplify this ambiguity when models treat incoming observations as comparable with historical training data and independent of prior actions. This article develops a conceptual account of how digital health signals should be translated into medication decisions when temporal drift, missingness, and intervention feedback coexist. The central proposition is that medication-oriented inference should distinguish changes in patient state from changes in the measurement system, observation process, model state, and intervention history before a longitudinal trajectory is treated as clinically actionable. The analysis further separates model updating from clinical escalation: recalibration, additional measurement, clinician review, model withholding, and retraining address different failure mechanisms and should not be treated as interchangeable responses to declining confidence. The resulting framework is intended to support longitudinal pharmaceutical care without assuming that repeated digital measurements are stationary, complete, or unaffected by previous therapeutic decisions.